In this article, learn about:
What the still-open Section 232 investigation covers, and what it leaves out
Why a report deadline that passed five months ago changes how importers should plan
How life sciences supply chain teams can map import exposure before a determination arrives
Supply chain leaders in life sciences who watched the pharmaceutical tariffs land this year could be forgiven for treating Section 232 as finished.
The proclamation arrived in April 2026, the rates phased in through September, and companies without onshoring deals are paying them now.
However, that framing misses a different Section 232 track. On September 2, 2025, the U.S. Department of Commerce opened a separate Section 232 investigation, covering personal protective equipment, medical consumables, and medical devices, but leaving pharmaceuticals out. This investigation has never produced a public decision and its report deadline passed roughly five months ago.
For companies that import gloves, syringes, infusion pumps, ventilators, stents, or imaging machines, the tariff question has remained open for more than a year.
What Already Happened With Section 232 Pharmaceutical Tariffs?
On April 2, 2026, President Trump signed Proclamation 11020, setting a 100% default duty on patented drugs and the active ingredients behind them, with lower rates tied to origin and to company commitments.
A trade update from customs broker GHY International records tariffs of 20% for companies with Commerce-approved onshoring plans, while goods from the European Union, Japan, South Korea, and Switzerland pay 15%. Generic drugs and biosimilars are out of scope for now.
The rollout was fast. Duties began on July 31, 2026 for the companies named in Annex III, and on September 29 for everyone else. Customs and Border Protection (CBP) issued filing guidance three times between July and late September. Each round changed the codes importers had to report, and one code was retired outright.
What Is the Section 232 Investigation Into Medical Devices and PPE?
The open investigation is a separate action with a separate scope. Commerce started it on September 2, 2025, and the Federal Register notice followed on September 26. It asks whether imports of personal protective equipment, medical consumables, and medical equipment threaten national security. The comment period closed on October 17, 2025, during which 817 comments were filed.
The notice clearly draws the line with the action on pharmaceuticals. Prescription drugs, biologics, and specialty drugs are all excluded, because Commerce examined those imports separately. Everything else in the clinical supply chain is in scope, including:
Personal protective equipment used in health care settings, such as surgical masks, N95 respirators, gloves, and gowns
Medical consumables, meaning single-use items such as syringes, needles, intravenous bags, catheters, and sutures
Medical equipment, meaning durable items such as wheelchairs, crutches, and hospital beds
Medical devices, from pacemakers, insulin pumps, and coronary stents to blood glucose monitors, computed tomography scanners, and ventilators
Commerce listed twelve criteria, with two of them pointing at sourcing structure rather than product type. The first is how far United States imports lean on a small number of suppliers or countries. The second is whether domestic capacity can realistically grow. A company that buys components from one or two countries sits closer to the center of that inquiry than one with a broad supplier base.
Why Does an Overdue Deadline Matter?
According to Section 232 of the Trade Expansion Act of 1962, the Commerce Secretary has 270 days from the start of an investigation to report findings to the President. The President then has 90 days to decide whether to act. Counting 270 days from September 2, 2025 puts the report deadline near May 30, 2026, which passed roughly five months ago.
However, The Bureau of Industry and Security (BIS) Section 232 Investigations page still lists the case as open. Most legal and trade commentary from late 2025 expected action in spring 2026, then stopped tracking the case once comments closed.
An overdue report matters because there might not be a warning period before tariffs are implemented. Pharmaceutical importers, for instance, got the proclamation in April and the first duties in July. A decision that has already missed its deadline could sit unresolved for another year and land with very little warning when it does arrive.
How Has the Medical Device Industry Responded?
Two industry groups filed comments against tariffs on this category. As Knobbe Martens reported, the Medical Device Manufacturers Association argued that tariffs would disrupt a global industry that already meets demand at home and meets strict regulatory standards. The Advanced Medical Technology Association filed eleven policy recommendations, with several asking for low-tariff or no-tariff terms with Europe, Japan, the United Kingdom, Mexico, Canada, Costa Rica, and the Dominican Republic.
How the Market Reacted
Markets priced in risk as soon as the news broke. Reuters reported that the S&P Health Care Equipment index fell 1.6% after Commerce disclosed the probes in late September 2025. GE HealthCare, Becton Dickinson, Stryker, Insulet, Intuitive Surgical, and ResMed fell between roughly 3% and 9%, while Abbott and Medtronic each slipped under 2%.
How Should Teams Map Exposure to Life Sciences Supply Chain Tariffs?
Teams that came through the pharmaceutical rollout with the least disruption had their import picture documented before the proclamation, since none of that work depends on knowing what Commerce will recommend.
Build an import inventory at the tariff-code level. Pull twelve months of entry data and list each item by its Harmonized Tariff Schedule code, yearly value, and country of origin. That view shows which parts of the catalog fall inside the published scope and which sit outside it.
Identify origin concentration. Commerce named supplier and country concentration as a criterion it is weighing, and the same concentration determines whether a company can shift sourcing quickly.
Model duty scenarios against full customs value. The pharmaceutical proclamation applied its rate to customs value. That surprised importers who had modeled against component cost. Running a range of rates against full declared value gives a planning figure you can defend.
Review what the pharmaceutical rollout required day to day. Importers reported new codes alongside existing ones, worked through three rounds of CBP guidance, and dropped a retired code on a fixed date. A decision here would likely create a similar paperwork load inside purchase orders, invoices, and customs filings.
Set internal trigger points. Qualifying a second supplier, reworking landed-cost terms, and filing for a tariff ruling each carry their own lead time. An overdue report makes a calendar-based plan unreliable, so these decisions work better tied to events than to dates.
Frequently Asked Questions
Are there tariffs on medical device imports right now?
No. Section 232 tariffs apply to medical devices, PPE, or medical consumables as of October 2026. The investigation is still open, and no report or proclamation has been published. Existing duties apply as they did before.
Do the pharmaceutical tariffs apply to medical devices?
They do not. The Federal Register notice for the device and PPE investigation says pharmaceuticals are excluded, because Commerce examined them separately. Proclamation 11020 covers patented drugs and their active ingredients, not equipment or consumables.
What would happen if Commerce issued its report?
If the report finds that imports threaten national security, the President has 90 days to decide whether to act, usually through tariffs or quotas. The President does not have to follow the Secretary’s recommendation. A decision could also narrow the published scope, since that action shows carve-outs and tiered rates are both on the table.
What Happens to Your Documentation if a Determination Lands?
A Section 232 decision in this category would arrive as a data problem before it arrives as a sourcing problem. New codes have to flow through purchase orders, invoices, and shipping documents across every trading partner, and they have to be right from the first entry. SPS Fulfillment electronic data interchange (EDI) handles that document exchange across the network. It is preparation for the paperwork a decision would create, not an answer to the sourcing question.
Not ready for that conversation? The Supply Chain Source has resources on tariff exposure and trading partner operations.
This article is for general information only and is not legal, customs, or trade compliance advice. Tariff classifications, duty rates, and filing requirements change frequently. Double-check your position with qualified trade counsel or your customs broker before making sourcing, classification, or filing decisions.